In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy

Seth J Rotz; Nathan Luebbering; Bradley P Dixon; Eleni Gavriilaki; Robert A Brodsky; Christopher E Dandoy; Sonata Jodele; Stella M Davies

doi:10.1182/bloodadvances.2017008250

In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy

Blood Adv. 2017 Aug 23;1(20):1632-1634. doi: 10.1182/bloodadvances.2017008250. eCollection 2017 Sep 12.

Authors

Seth J Rotz¹, Nathan Luebbering¹, Bradley P Dixon², Eleni Gavriilaki^{3

4}, Robert A Brodsky⁴, Christopher E Dandoy¹, Sonata Jodele¹, Stella M Davies¹

Affiliations

¹ Division of Bone Marrow Transplantation and Immune Deficiency and.
² Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
³ Bone Marrow Transplantation Unit, Hematology Department, G. Papanicolaou Hospital, Thessaloniki, Greece; and.
⁴ Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.

Abstract

Transplantation-associated thrombotic microangiopathy is associated with complement activation in vitro.This data further supports the use of eculizumab for the treatment of patients with TA-TMA.

Grants and funding

R01 HL133113/HL/NHLBI NIH HHS/United States